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Abstract
Objective:
Peripheral intravenous catheter (PIVC) failure occurs frequently, but the underlying mechanisms of failure
are poorly understood. We aim to identify factors that predict premature PIVC failure.
Methods:
We conducted a single site prospective observational investigation at an academic tertiary care center.
Adult emergency department (ED) patients who underwent traditional PIVC placement in the ED and
required admission with an anticipated hospital length of stay greater than 48 hours were included.
Ongoing daily PIVC assessments included clinical and ultrasonographic evaluations. The primary goal
was to identify demographic, clinical, and PIVC related variables that predicted PIVC failure. Univariate
and multivariate analyses were employed to identify risk factors for PIVC failure.
Results:
In July and August of 2020, 62 PIVCs were enrolled. PIVC failure occurred in 24 (38.71%) participants.
Multivariate logistic regression demonstrated that the presence of subcutaneous edema [AOR 8.29 (1.50,
45.8) p = 0.0153], an above average neutrophil to lymphocyte (N:L) ratio [AOR 4.63 (1.06, 20.3) p =
0.0422], and the administration of an irritant/vesicant [10.3 (1.46, 72.6) p = 0.0.192] were associated with
increased likelihood of premature PIVC failure.
Conclusions:
PIVC failure is related to clinical and ultrasonographic variables associated with inflammation: elevated
N:L ratio, use of caustic medications, and presence of subcutaneous edema on ultrasound. Reducing
inflammation of the vein may lead to better PIVC survival outcomes. Further large-scale randomized
controlled trials are needed to validate and build upon the concepts in this study.

Introduction
The placement of peripheral intravenous catheters (PIVC) is the most commonly performed invasive
procedure in the acute care clinical setting with over 300 million PIVCs inserted annually in the United
States alone.1–3 Up to 90% of hospitalized patients require a PIVC for therapy with many patients relying
on functional vascular access for the delivery of life-saving fluids and medications.1 Unfortunately, PIVCs
have high failure rates ranging from 36% to 63% leading to significant patient safety and cost
implications.2–4 Patients may suffer a multitude of sequelae from PIVC failure including extravasation
with skin necrosis, catheter associated bloodstream infections, interruption of medical therapies, and
longer hospital stays.5–7 Further, PIVC failure results in additional invasive procedures to obtain vascular
access often requiring multiple needle sticks and reinsertions that may lead to venous depletion leaving
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limited or no viable peripheral venous access options. Once venous depletion develops PIVC insertion
becomes more difficult and it is estimated that up to 3% of patients require a central venous access
device.8
A better understanding of the etiology of PIVC failure is critical to improve patient outcomes. Most of the
existing literature highlights the various causes of PIVC failure (phlebitis, infiltration, occlusion) but as
presence of these complications generally equates to need for catheter removal, once the complication is
externally evident, little can be done to reverse course.9 Prevention of these complications requires
focusing on the changes beneath the skin that begin soon after PIVC insertion and progress over
time.10,11 Thus, investigating the anatomical changes at the subcutaneous level after PIVC insertion may
unlock the secret to improved survivorship. Some recent exploratory data indicates that PIVC failure is
due to ongoing inflammation of the vein.12,13 Internally, venous changes can include narrowing of vein
wall, wall thickening, and presence of thrombus even in the absence of any clinical signs and
symptoms.11 The incorporation of venous duplex ultrasonography to the site evaluation provides an
objective means to characterize the ongoing changes underneath the skin and may help identify
inflammatory variables that lead to PIVC failure.
The goal of this investigation is to create a predictive model for PIVC failure based upon our hypothesis
that inflammation is the root cause of the problem. We aim to use demographic, clinical, and sonographic
variables to identify risk factors associated with PIVC failure.

Materials And Methods
Study Design, Setting, and Selection of Participants
This study was a prospective observational investigation of PIVC failure. The study was conducted at a
large 1100 bed tertiary care center with an annual ED census of greater than 130,000 visits. The
Beaumont Institutional Review Board (IRB) approved this study.
Study investigators recruited a convenience sample of ED patients meeting inclusion criteria. Patients
aged at least 18 years with anticipated hospitalization of greater than 48 hours and a PIVC placed using
direct visualization and/or palpation in the ED were eligible participants. Patients admitted to the high
acuity progressive and intensive care units were specifically targeted to increase the likelihood of meeting
the minimum hospital length of stay goal of 48 hours. Patients were excluded if they voluntary withdrew
or were cognitively impairment. Additionally, if the PIVC was inserted with ultrasound guidance or if the
first sonographic assessment could not be conducted within 24 hours of PIVC placement then the patient
was not eligible for enrollment. Informed consent was obtained for all subjects prior to enrollment in the
study. All procedures performed in this study were in accordance with the ethical standards of the
institutional research committee and with the Declaration of Helsinki.
Study Procedure
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After patient enrollment, researchers performed an initial assessment of the patient. Pertinent
demographic and clinical data was abstracted from the electronic medical record (EMR) and included
age, body mass index, admission blood pressure, admission heart rate, gender, smoking history, preexisting medical conditions (diabetes, deep vein thrombosis history, clotting disorder, cancer), and use of
anticoagulant medications.
PIVC function was confirmed by clinical assessment (per institutional standard), in which a functional
PIVC can be flushed without resistance and shows no external signs of unresolvable complication. PIVC
complications include pain and/or tenderness, redness, and leaking or swelling around the PIVC site.
PIVC failure was defined as failure of functionality based upon the clinical treatment team’s impression.
Next, the investigator performed a sonographic evaluation of the PIVC and surrounding area using a
uniform scanning technique that has been previously described in the literature.14 Study investigators
trained in using ultrasound were responsible for obtaining images. The Mindray M7 Ultrasound Machine
with a 14 MHz high frequency linear array transducer was used for all sonographic evaluations. After a
small amount of sterile gel was placed on the non-bordered transparent dressing proximal to the PIVC
insertion site, the PIVC and surrounding tissue was scanned proximally (towards the heart) 10 cm
(length) x 5 cm (width) in short axis extending from the hub of the PIVC. Similar scanning was performed
over the same area in the long axis. Appendix A demonstrates scan area. Adequate placement of the
PIVC within the vein was confirmed using ultrasound. Gel was wiped off the dressing and skin after the
imaging took place.
A series of cine clips (five seconds duration) of the scan area were recorded. All ultrasound images were
saved and archived in QPath, a secure and Health Insurance Portability and Accountability Act (HIPPA)
compliant storage warehouse for review and interpretation by the Emergency Ultrasound Director. The
following measurements were made by post-processing of the original images: catheter-to-vein ratio,
length of catheter in vein, angle of insertion, angle of distal tip against vessel wall, vein wall thickness,
distance of catheter tip to vessel wall, degree of catheter kinking, and size of thrombus formation
(Appendix B).
Investigators performed follow-up ultrasound and clinical assessments on all catheters daily for the life
of the PIVC. At each follow-up interval, the researcher documented the time of evaluation and performed
a sonographic assessment using the identical method as described above for the initial assessment.
These images were also saved and archived similar to the index evaluation.
Clinical staff documents functional status of PIVCs in the EMR as a standard of care measure within our
institution. Daily assessment of catheter function was accomplished by reviewing this documentation in
the EMR for any notation of catheter failure and complications. If the investigators had any questions or
concerns regarding the functionality of the PIVC, clinical staff was brought to the bedside to reassess
functionality the PIVC. If the catheter failed or was removed prior to a follow-up assessment, the PIVC
failure time, assessment of failure, and reason for line removal was obtained though EMR review and
discussion with the nursing staff when possible.
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Within 24 hours of PIVC placement, researchers used ultrasound to assess the PIVC site by measuring the
diameter of the vein, length of the catheter in the vein, the angle of PIVC insertion, and the angle of the
distal tip of the catheter to the vessel wall (Appendix B). After initial assessment of the PIVC, researchers
continued to monitor the PIVC and surrounding tissue on a daily basis to follow the progression of the
complication. Daily measurements included vein wall thickness, distance of catheter tip to vessel wall,
degree of catheter kinking, as well as the assessment of thrombus or subcutaneous edema (Appendix C).
During every ultrasound evaluation, the insertion site was examined by the researcher and assessed
using a standardize visual phlebitis scale.9 The participant was considered symptomatic if they received
a score of grade 1 or greater based on a standardized phlebitis scale, which includes the presence of
erythema, pain, and/or edema at the access site.9 All medications administered through each catheter
was queried and cross referenced against known irritants and vesicants, as defined by the Infusion
Nursing Society.15 Frequency of administration and dosages were recorded. Beyond vesicants and
irritants, the number of overall catheter events were recorded. A catheter event was defined as any
instance where fluid was administered through the catheter, including administration of a bolus, initiation
of a drip, non-irritant medication administration. Flushing was considered a component of routine care
and PIVC maintenance and was not considered an independent event.
Outcome Measures
The primary endpoint was to identify risk factors associated with premature PIVC failure.
Statistical Rationale and Analysis
Continuously measured variables were displayed in terms of mean/average with standard deviation while
categorical variables were displayed as frequencies with percentages in parentheses. Univariate, or
unadjusted, analysis was performed. Continuous variables were stratified by catheter failure and
compared using a Two Samples Independent T-Tests. Categorical variables also were stratified by
catheter failure and compared using Chi-Square tests. Odds Ratios (OR) with corresponding 95%
Confidence Intervals (95% CI) also were displayed for categorical variables. In addition, univariate logistic
regression models were used and results were displayed in terms of Odds Ratios (OR) with corresponding
95% CI and P-Values. Kaplan-Meier Curves were graphically generated to show the difference in time-toevent outcomes in selected characteristics.
Multivariate/adjusted models also were generated as part of this study. Variables included in these
models were chosen by all authors based on clinical rationale and the univariate/unadjusted findings.
Firth’s Penalized Likelihood was employed to mitigate the potential bias caused by the relatively small
sample.16 A multivariate logistic regression model was used. Effect sizes were shown in terms of
Adjusted Odds Ratios (AOR) with 95% CI and P-Values for the logistic model.
P-Value < 0.05 indicates a statistically significant finding. All significant findings represent associations
as no formal attempts were made to identify cause-and-effect, or causal, relationships. All analysis was
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performed in SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

Results
In July and August of 2020, 77 patients were consented for the study, of these, 15 participants were
excluded. 11 of these patients were lost to follow up (5 PIVCs failed and 7 patients were discharged prior
to the first ultrasound evaluation), 3 PIVCs were excluded as two had incomplete PIVC documentation in
the chart and one patient voluntarily withdrew from the study. Of the remaining 62 PIVCs, 24 (38.7%) met
criteria for premature failure and 38 (61.2%) survived to completion of therapy. The mean catheter dwell
time was 76.42 hours (SD = 66.60).
Patient characteristics and comorbidities were similar between the catheters that failed and survived to
completion of therapy (all P ≥ 0.05). Among the 62 patients in the final cohort, 53 had available complete
blood count with differential data from admission and were assessed for neutrophil and lymphocyte. The
average neutrophil count in failed PIVCs was 10.77 (SD = 4.15), vs 5.41 (P < 0.0001) in PIVCs that
survived to treatment completion. Similarly, the average Neutrophil to Lymphocyte (N:L) ratio was 12.12
(SD = 8.52) in the failed PIVC group, compared to 5.29 (SD = 4.44) in the group of PIVCs that survived to
completion of therapy (P = 0.0018) (Table 1).
Our analysis showed a significant association between subcutaneous edema and catheter failure; while
57.14% of PIVC’s that had subcutaneous edema failed, only 14.81% of PIVC’s without subcutaneous
edema failed (P = 0.0020) (Figure 1A). There is also a significant association between premature catheter
failure and the administration of vesicants/irritants (P = 0.0064) (Figure 1B). There also are findings
linking catheter failure to usage of the PIVC. The number of catheter events that occurred during the life
of the catheter in the survival group was 3.39, which was significantly less than the failure group at 5.58
(P = 0.0011). In terms of the number of days the catheter is idle, the average percent of days idle for the
survival group was 38%, compared to just 6% in the failure group (P < 0.0001) (Table 2).
Unadjusted for other factors, logistic regression analysis demonstrated that subcutaneous edema was
associated with 6.91-fold greater odds of catheter failure (P = 0.0020). At the time of admission, those
with an N:L ratio of ≥ 8.1 demonstrated 6.85-fold greater odds of catheter failure (P = 0.0029). Patients
with more than one PIVC present throughout their hospital course were associated with greater odds of
catheter failure (OR = 6.53; P = 0.0044). In regards to IV infusates, the administration of
vesicants/irritants was linked to 8.95-fold greater odds of premature catheter failure (P = 0.0064) (Table
3).
Multivariate logistic regression analysis, which was adjusted for other factors, demonstrated
subcutaneous edema was independently associated with 8.29-fold greater odds of premature catheter
failure (P = 0.0153). Additionally, those with N:L ratio of > 8.1 had 4.63-fold greater odds of premature
catheter failure (P = 0.0422). Furthermore, administration of a vesicant/irritant to the PIVC was
associated with 10.3-fold greater odds of premature PIVC failure (P = 0.0192) (Table 3).
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Discussion
We found that the presence of subcutaneous edema, a N:L ratio of ≥8.1, and administration of
vesicants/irritants were predictive of PIVC failure. These results supported our hypothesis that
inflammation is a major contributor to poor PIVC survivorship. Our study added to the growing body of
literature that has identified subcutaneous edema, a marker of inflammation, as a relevant variable in
PIVC outcomes. Further, to our knowledge, this is the first investigation that identifies subcutaneous
edema as a major predictor of PIVC failure. Additionally, we discovered that an increased neutrophil to
lymphocyte ratio increased the risk of PIVC failure, suggesting further investigation is needed to better
understand these mechanisms on a cellular level.
Existing prediction models for PIVC failure are sparse. In one multivariate analysis, traditional inserterrelated variables such as catheter diameter and site of insertion were linked to PIVC failure.1 The authors
concluded that smaller catheter diameters and forearm placement were associated with the best PIVC
survival rates. As the wrist and hands have the worst outcomes and no catheters in our study were placed
in these locations, this variable was not a relevant predictor in our cohort.4 Additionally, a catheter to vein
ratio of less than 0.33 has been identified as a risk factor for catheter failure. In our study over 80% of the
catheters were 20-gauge in diameter and the average catheter to vein ratio was 0.36, suggesting that the
impact of catheter diameter on PIVC failure was also likely minimal in our cohort.17 Despite what would
appear as optimal PIVC conditions according to prior research, we still noted a high failure rate of 38.7%
highlighting the need for further investigation.
Other trials have recently implicated mechanical irritation of the vein wall as a strong predictor of
catheter-induced inflammation. In an analysis on the location of catheter tip position within the vein,
Murayama et al. found that contact of the tip against the vein wall was associated with subcutaneous
edema on ultrasound.14 Another study in an animal model found that modification of the catheter with
the goal of reducing contact against the vein wall led to a 40% reduction in subcutaneous edema.18 In our
study, not only did we identify that subcutaneous edema existed in the majority of our insertions, but we
also found that subcutaneous edema on ultrasound was a significant predictor of PIVC failure, a key
clinical outcome measure. However, unlike previous investigations, we tracked onset and progression of
subcutaneous changes using an innovative methodology inclusive of daily ultrasound site assessments.
Serial tracking helped identify that the location of the tip of the catheter was not a static condition, but
rather a variable that potentially changed daily. In 44 (71%) cases, the catheter tip to wall distance varied
among serial ultrasound evaluations. In 87% of cases, the catheter tip contacted the vein wall at least
once during its lifespan illustrating that irritation from the tip likely occurs in more PIVCs than previously
reported.14 It also highlights that PIVC tip position is not a static variable and natural ebbs and flows in
the degree of inflammation caused by mobility of the catheter should be considered when seeking
solutions to the PIVC failure problem.
We identified that ultrasonographic changes began very early after PIVC insertion.
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Indeed, laboratory models have demonstrated that the release of inflammatory and pro-thrombotic
markers begins as early as the initial IV needlestick.19 We found that thrombosis was a nearly universal
occurrence with 87% of PIVCs having some degree of catheter-associated thrombosis. This is likely due
to the initial cascade of inflammatory markers that is released during PIVC insertion.14 We noted that in
many cases, thrombus formation occurred rapidly, with 52% of patients developing thrombosis within 24
hours of PIVC placement. However, not all thrombosis was clinically significant. We noticed that a subset
of patients had no progression or change in the ultrasonographic site assessment, while a larger group
had significant progression and eventual development of subcutaneous edema. These findings suggest
that while initial release of inflammatory and pro-thrombotic markers is likely inevitable, their continued
release is a key step in premature PIVC failure. Therefore, to improve PIVC survival methods to reduce
continued inflammatory marker release are needed. While reducing continued inflammatory marker
release is likely achievable by mechanical modification of the PIVC position, our research also elucidated
another potential target to help reduce the rate of PIVC failure.
Cellular models show that significant ongoing inflammatory marker release results in local neutrophil
recruitment, activation, and neutrophil extracellular trap (NET) formation. NET formation has recently
been implemented in a variety of pathologic, pro-thrombotic, conditions such as stroke, myocardial
infarction, and deep venous thrombosis.20 Thrombosis in the presence of NETs is resistant to normal
mechanisms of clot degradation.20 We found that increased neutrophil to lymphocyte N:L ratio as well as
a higher circulating neutrophil count was predictive of PIVC failure. In multivariate analysis, we found that
N:L ratio of > 8.1 had 4.63-fold greater odds of premature catheter failure. Our data confirms that while
thrombus was almost universal, only once significant signs of inflammation were present did premature
PIVC failure occur. Therefore, ongoing inflammatory marker release resulting in local neutrophil activation
which leads to “inflammatory NET thrombus” is likely a key component of premature catheter failure.
Thus, in addition to modifying mechanical PIVC factors to reduce ongoing inflammation, another strategy
to increase PIVC survival may be prevention of NET thrombosis formation, rather than simple
antithrombogenic coatings that have been recommended previously.
This study took place during the COVID pandemic, thus only a small sample size was obtained due to
personal protective equipment limitations and research regulations within the hospital. Given the small
sample size, effects of certain variables on PIVC failure may be underestimated, particularly factors with
marginal significance. Further, the findings may not be generalized to all settings as the study was
conducted at a large academic tertiary care center with a unique population. Additionally, if the PIVC
failed or patients were discharged during off hours, the final determination of whether a PIVC was
considered a success or failure was based on documentation within the study participant’s medical
record. In some instances, the researchers found PIVCs with sonographic signs of severe inflammation,
but clinical staff was not available to perform bedside functionality assessment of the catheter. It is
possible that there may have been a delay in the recognition of PIVC complication and failure in some
cases.
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This study's findings demonstrate that the presence of subcutaneous edema, an increasing N:L ratio, and
the administration of vesicants/irritants increase the risk of premature PIVC failure. Inflammation plays a
key role in precipitating PIVC failure and solutions targeting reduction in inflammation may substantially
improve PIVC outcomes. Additional larger, prospective research investigations are needed to validate and
build upon these findings.
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All PIVCs
(n = 62)

Failed
(n = 24)

Survived
(n = 38)

P-Value

67.18 (19.25)

65.79 (18.12)

68.05 (20.12)

0.6561

Male

32 (51.61%)

14 (43.75%)

18 (56.25%)

Female

30 (48.39%)

10 (33.33%)

20 (66.67%)

0.4178

28.22 (6.82)

29.22 (7.26)

27.58 (6.56)

0.3632

No

32 (51.61%)

13 (40.63%)

19 (59.38%)

Yes

30 (48.39%)

11 (36.67%)

19 (63.33%)

No

45 (72.58%)

15 (33.33%)

30 (66.67%)

Yes

17 (27.42%)

9 (52.94%)

8 (47.06%)

No

54 (87.10%)

22 (40.74%)

32 (59.26%)

Yes

8 (12.90%)

2 (25.00%)

6 (75.00%)

No

55 (88.71%)

20 (36.36%)

35 (63.64%)

Yes

7 (11.29%)

4 (57.14%)

3 (42.86%)

No

54 (87.10%)

19 (35.19%)

35 (64.81%)

Yes

8 (12.90%)

5 (62.50%)

3 (37.50%)

Patient Characteristics
Age of Patient (Years)
Mean (Standard Deviation)
Gender

Body Mass Index (BMI) of Patient
Mean (Standard Deviation)
Comorbidities
History of Smoking

0.7588

History of Diabetes

0.1735

History of Active Cancer

0.4820

History of Previous DVT

0.3243

Personal History of Clotting Disorder

0.1774

Currently on Anticoagulant Medication
No

45 (72.58%)

18 (40.00%)

27 (60.00%)

Yes

17 (27.42%)

6 (35.29%)

11 (64.71%)

Vital Signs at Time of Admission
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0.7676

Systolic Blood Pressure at Admission
Mean (Standard Deviation)

131.95 (20.82)

126.08 (18.68)

135.66 (21.47)

0.0775

84.56 (22.14)

98.75 (22.01)

75.61 (17.15)

< 0.0001

(n = 53)

(n = 22)

(n = 31)

7.64 (4.36)

10.77 (4.15)

5.41 (2.94)

(n = 53)

(n = 22)

(n = 31)

8.12 (7.23)

12.12 (8.52)

5.29 (4.44)

(n = 53)

(n = 22)

(n = 31)

Yes

17 (32.08%)

12 (70.59%)

5 (29.41%)

No

36 (67.92%)

10 (27.78%)

26 (72.22%)

(n = 53)

(n = 22)

(n = 31)

1.31 (0.72)

1.20 (0.77)

1.38 (0.69)

0.3726

Left

27 (43.55%)

12 (44.44%)

15 (55.56%)

0.4282

Right

35 (56.45%)

12 (34.29%)

23 (65.71%)

Antecubital

47 (75.81%)

20 (42.55%)

27 (57.45%)

Forearm

15 (24.19%)

4 (26.67%)

11 (73.33%)

No

47 (75.81%)

13 (27.66%)

34 (72.34%)

Yes

15 (24.19%)

11 (73.33%)

4 (26.67%)

0.0044

0.7951

Heart Rate at Admission
Mean (Standard Deviation)
Lab Values at Time of Admission
Neutrophils
Mean (Standard Deviation)
NL Ratio
Mean (Standard Deviation)
NL Ratio > 8.5

Lymphocytes
Mean (Standard Deviation)

< 0.0001

0.0018

0.0066

IV Insertion Characteristics
Laterality of Successful Cannulation

Location of IV

0.3180

>1 IV Placed During Hospital Course

Catheter Gauge (including diameter in mm)
18: 1.27 mm

12 (19.35%)

5 (41.67%)

7 (58.33%)

20: 0.91 mm

50 (80.65%)

19 (38.00%)

31 (62.00%)

0.10 (0.01)

0.10 (0.01)

0.10 (0.01)

Diameter of Catheter (cm)
Mean (Standard Deviation)
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0.8185

Vein Diameter (short axis) (cm)
Mean (Standard Deviation)

0.32 (0.13)

0.32 (0.14)

0.33 (0.13)

0.6888

0.36 (0.15)

0.37 (0.16)

0.35 (0.15)

0.5999

1.95 (0.44)

2.00 (0.32)

0.5949

15.00 (4.58)

15.61 (7.43)

0.6953

6.37 (5.09)

0.6039

Catheter-to-vein ratio
Mean (Standard Deviation)

Length of Catheter in Vein (long axis) (cm)
Mean (Standard Deviation)

1.98 (0.37)

Angle of Insertion (long axis) (degrees)
Mean (Standard Deviation)

15.38 (6.47)

Angle of Distal Tip Against Vessel Wall (long axis) (degrees)
Mean (Standard Deviation)

6.10 (5.13)

5.67 (5.28)

Table 2: Daily IV Characteristics, Clinical Symptoms, Sonographic Findings, IV Infusate Administration,
and IV Usage Characteristics
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All Lines
(n = 62)

Failed
(n = 24)

Survived
(n = 38)

P-Value

0.04 (0.01)

0.04 (0.02)

0.05 (0.01)

0.5931

0.03 (0.03)

0.04 (0.05)

0.0561

4.17 (3.31)

4.36 (3.28)

4.06 (3.37)

0.7316

0

36 (58.06%)

12 (33.33%)

24 (66.67%)

1

20 (32.26%)

9 (45.00%)

11 (55.00%)

2

6 (9.68%)

3 (50.00%)

3 (50.00%)

(n = 54)

(n = 22)

(n = 32)

Symptomatic

22 (40.74%)

11 (50.00%)

11 (50.00%)

Asymptomatic

32 (59.26%)

11 (34.38%)

21 (65.63%)

No

27 (43.55%)

4 (14.81%)

23 (85.19%)

Yes

35 (56.45%)

20 (57.14%)

15 (42.86%)

(n = 35)

(n = 20)

(n = 15)

Mean (Standard Deviation)

46.92 (52.32)

39.17 (34.61)

57.25 (69.44)

< 24 Hours

8 (22.86%)

6 (75.00%)

2 (25.00%)

24 - 48 Hours

18 (51.43%)

10 (55.56%)

8 (44.44%)

> 48 Hours

9 (25.71%)

4 (44.44%)

5 (55.56%)

(n = 54)

(n = 22)

(n = 32)

Yes

40 (74.07%)

17 (42.50%)

23 (57.50%)

No

14 (25.93%)

5 (35.71%)

9 (64.29%)

(n = 54)

(n = 22)

(n = 32)

Daily IV Characteristics
Vein Wall Thickness (short axis) (cm)
Mean (Standard Deviation)

Distance of Catheter Tip to Vessel Wall (cm)
Mean (Standard Deviation)

0.04 (0.04)

Degree of Catheter Kinking (long axis) (degrees)
Mean (Standard Deviation)
Clinical Symptoms
Phlebitis Scale (0-5)

Phlebitis

0.5963

0.2682

Sonographic Findings
Presence of subcutaneous edema

Time to Edema

Presence of Thrombus

Time to Thrombus
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0.0020

0.3660

0.5333

0.6941

Mean (Standard Deviation)

26.22 (19.88)

23.57 (14.94)

28.05 (22.71)

0.3862

< 24 Hours

28 (51.85%)

12 (42.86%)

16 (57.14%)

24 Hours +

26 (48.15%)

10 (38.46%)

16 (61.54%)

0.7535

0.2450

IV Infusate Administration
IV fluid bolus or continuous drip administered
Yes

49 (79.03%)

21 (42.86%)

28 (57.14%)

No

13 (20.97%)

3 (23.08%)

10 (76.92%)

No

11 (17.74%)

1 (9.09%)

10 (90.91%)

Yes

51 (82.26%)

23 (45.10%)

28 (54.90%)

0.0661

No

11 (17.74%)

9 (81.82%)

2 (18.18%)

0.0064

Yes

51 (82.26%)

15 (29.41%)

36 (70.59%)

76.42 (66.60)

66.85 (44.34)

82.47 (77.42)

0.3171

4.24 (2.65)

5.58 (2.41)

3.39 (2.47)

0.0011

26% (31%)

6% (17%)

38% (32%)

< 0.0001

IV Medication Administration

IV Vesicant/Irritant Administration

IV Usage Characteristics
Catheter Dwell Time (Hours)
Mean (Standard Deviation)
Number of Catheter Events
Mean (Standard Deviation)
Percent of Days Idle (%)
Mean (Standard Deviation)

Table 3: Univariate and Multivariate Analysis
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Univariate
OR (95% CI)

Multivariate
P-Value

AOR (95% CI)

P-Value

4.63 (1.06, 20.3)

0.0422

Patient Characteristics
Gender
Male

Reference Group

Female

0.65 (0.23, 1.83)

0.4178

Comorbidities
History of Smoking
No

Reference Group

Yes

0.85 (0.31, 2.37)

0.7588

History of Diabetes
No

Reference Group

Yes

2.20 (0.71, 6.85)

0.1735

History of Active Cancer
No

Reference Group

Yes

0.56 (0.11, 2.86)

0.4820

History of Previous DVT
No

Reference Group

Yes

2.23 (0.45, 10.9)

0.3243

Personal History of Clotting Disorder
No

Reference Group

Yes

2.86 (0.62, 13.2)

0.1774

Currently on Anticoagulant Medication
No

Reference Group

Yes

0.84 (0.27, 2.67)

0.7676

Yes

6.85 (1.93, 24.3)

0.0029

No

Reference Group

Lab Values at Time of Admission
NL Ratio > 8.1
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Reference Group

N:L Ratio

1.19 (1.05, 1.34)

0.0052

Left

1.52 (0.54, 4.25)

0.4282

Right

Reference Group

IV Insertion Characteristics
Laterality of Successful Cannulation

Location of IV
Antecubital

Reference Group

Forearm

0.53 (0.15, 1.86)

0.3180

>1 IV Placed During Hospital Course
No

Reference Group

Yes

6.53 (1.79, 23.8)

0.0044

Catheter Gauge (including diameter in mm)
18: 1.27 mm

1.19 (0.33, 4.26)

20: 0.91 mm

Reference Group

0.7951

Catheter-to-Vein Ratio
Ratio > 33%

1.23 (0.44, 3.42)

0.6935

0.91 (0.21, 3.97)

0.8996

Ratio < 33%

Reference Group

Reference Group

0 only

Reference Group

Reference Group

0 and > 0

0.80 (0.25, 2.50)

0.6962

0.34 (0.07, 1.81)

0.2076

> 0 only

0.48 (0.08, 2.89)

0.4187

1.13 (0.09, 14.2)

0.9267

Daily IV Characteristics
Distance Catheter Tip to Vein Wall

Clinical Symptoms
Phlebitis Scale (0-5)
0

Reference Group

1

1.62 (0.53, 4.96)

0.3987

2

1.96 (0.34, 11.2)

0.4495

1.87 (0.62, 5.66)

0.2682

Phlebitis
Symptomatic
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Asymptomatic

Reference Group

Sonographic Findings
Subcutaneous Edema
Yes

6.91 (2.03, 23.5)

No

Reference Group

0.0020

8.29 (1.50, 45.8)

0.0153

Reference Group

Time to Edema
< 24 Hours

Reference Group

24 - 48 Hours

0.48 (0.08, 2.89)

0.4190

> 48 Hours

0.32 (0.04, 2.40)

0.2642

Yes

1.29 (0.37, 4.51)

0.6941

No

Reference Group

Presence of Thrombus

Time to Thrombus
< 24 Hours

Reference Group

24 Hours +

0.84 (0.28, 2.49)

0.7535

IV Infusate Administration
IV Fluid Bolus or Continuous Drip Administered
Yes

2.26 (0.57, 8.97)

No

Reference Group

0.2450

IV Medication Administered
No

Reference Group

Yes

5.77 (0.89, 37.5)

0.0661

Yes

8.95 (1.85, 43.2)

0.0064

No

Reference Group

Vesicant/Irritant Administered

Figures
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10.3 (1.46, 72.6)
Reference Group

0.0192

Figure 1
Kaplan-Meier survival curve estimates for PIVC survival. Each plot indicates the survival probability of 0.5
with its corresponding median dwell time. A. The median survival time was 77.69 hours (95% CI: 52.60
hours, 148.50 hours) for participants with subcutaneous edema and 104.23 hours (not enough data to
compute a CI for the median) for participants without subcutaneous edema. B. The median survival time
was 55.37 hours (95% CI: 35.00 hours, 72.27 hours) for subjects who were administered
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vesicants/irritants and 148.50 hours (not enough data to compute a CI for the median) for subjects who
were not administered any vesicants/irritants.
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